FindTrial
Sign In

Epsilon-aminocaproic Acid versus Tranexamic Acid in reducing blood loss in Total Hip/knee Arthroplasty

Epsilon-aminocaproic Acid versus Tranexamic Acid in reducing blood loss in Total Hip/knee Arthroplasty:A Prospective Randomised controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000032271
Enrollment
Unknown
Registered
2020-04-25
Start date
2020-04-30
Completion date
Unknown
Last updated
2020-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthroplasty

Interventions

A:e-aminocaproic acid
B:Tranexamic acid

Sponsors

Department of Orthopaedic Surgery, West China Hospital, West China Medical School, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Primary unilateral total hip artropasty; 2. Patients with end-stage osteoarthritis or ONFH (osteonecrosis of the Femoral Head); 3. Able and willing to provide signed informed consent.

Exclusion criteria

Exclusion criteria: Exclusion criteria included revision or bilateral procedures, previous ipsilateral hip/knee surgery, contraindications for the use of TXA and EACA(allergy or history of blood clot events within 6 months), American Society of Anesthesiologists (ASA) grade IV or greater, preoperative anemia (hemoglobin [Hb] level of 35 kg/m2 and coagulation disorders.

Design outcomes

Primary

MeasureTime frame
Blood loss;Transfusion rates;Transfusion units;Maximum Hb drop;—

Secondary

MeasureTime frame
Hb level on postoperative days 1 and 3;length of stay;complications;HB;HCT;CRP;ESR;—

Countries

China

Contacts

Public ContactShen Bin

Department of Orthopaedics, West China Hospital, Sichuan University

shenbin_1971@163.com+86 18980601390

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026